PicoCELA (NASDAQ:PCLA) Releases Quarterly Earnings Results

PicoCELA (NASDAQ:PCLA) issued its quarterly earnings data on Friday. The company reported ($3.30) earnings per share (EPS) for the quarter, FiscalAI reports. The firm had revenue of $1.16 million during the quarter.

PicoCELA Stock Performance

NASDAQ:PCLA traded down $0.09 on Friday, reaching $6.95. 69,407 shares of the stock traded hands, compared to its average volume of 697,244. PicoCELA has a 1-year low of $1.35 and a 1-year high of $19.61. The company’s 50 day moving average is $6.46 and its 200-day moving average is $4.68.

Analyst Ratings Changes

Several research firms recently issued reports on PCLA. Weiss Ratings upgraded shares of PicoCELA from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 17th. Wall Street Zen upgraded PicoCELA to a “hold” rating in a research report on Saturday, July 25th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

PicoCELA Company Profile

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.